Presenting at ASCO 2019

Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs)

Author(s): Sean Khozin, Mark S. Walker, Monika Jun, Li Chen, Edward Stepanski, Wendy S. Rubinstein, George Anthony Komatsoulis, Jeremy Roberts, Jizu Zhi, Robert S. Miller, Ryan Fukushima, Denise Lau, Brigham Hyde; U.S. Food and Drug Administration, Silver Spring, MD; ACORN Research LLC, Memphis, TN; Concerto HealthAI, Boston, MA; American Society of Clinical Oncology’s (ASCO) CancerLinQ, Alexandria, VA; Tempus, Chicago, IL
At: 2019 ASCO Annual Meeting, Clinical Science Symposium

Read the full text here >>

ASCO Annual Meeting 2019

Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients

Author(s): Smita Agrawal, Vivek Vaidya, Prajwal Chandrashekaraiah, Hemant Kulkarni, Li Chen, Karl Rudeen, Babu Narayanan, Orr Inbar, Brigham Hyde; Concerto HealthAI, Bengaluru, India; Concerto Health AI, Bengaluru, India; Concerto HealthAI, Bangalore, India; Concerto Health AI, Banglore , India; Concerto HealthAI, Boston, MA; Concerto Health AI, New York, NY; Concerto Health AI, Ra’anana, Israel
At: 2019 ASCO Annual Meeting, Poster Session

Read the full text here >>

Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ

Author(s): Wendy S. Rubinstein, Li Chen, George Anthony Komatsoulis, Edward Stepanski, Monika Jun, Jizu Zhi, Denise Lau, Jeremy Roberts, Robert S. Miller, Mark S. Walker, Ryan Fukushima, Brigham Hyde, Sean Khozin; American Society of Clinical Oncology’s (ASCO) CancerLinQ, Alexandria, VA; Concerto HealthAI, Boston, MA; Precision Health AI, New York, NY; U.S. Food and Drug Administration, Silver Spring, MD; Tempus, Chicago, IL; ASCO’s CancerLinQ, Alexandria, VA; ACORN Research LLC, Memphis, TN
At: 2019 ASCO Annual Meeting, Poster Session

Read the full text here >>

Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database

Author(s): Li Chen, Mark S. Walker, Jizu Zhi, George Anthony Komatsoulis, Monika Jun, Edward Stepanski, Ryan Fukushima, Denise Lau, Jeremy Roberts, Brigham Hyde, Robert S. Miller, Sean Khozin, Wendy S. Rubinstein; Concerto HealthAI, Boston, MA; U.S. Food and Drug Administration, Silver Spring, MD; American Society of Clinical Oncology’s (ASCO) CancerLinQ, Alexandria, VA; Tempus, Chicago, IL
At: 2019 ASCO Annual Meeting, Poster Session

Read the full text here >>

Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor

Author(s): Sean Khozin, Jizu Zhi, Monika Jun, Li Chen, Wendy S. Rubinstein, Mark S. Walker, George Anthony Komatsoulis, Jeremy Roberts, Ryan Fukushima, Denise Lau, Brigham Hyde, Edward Stepanski, Robert S. Miller; U.S. Food and Drug Administration, Silver Spring, MD; Concerto HealthAI, Boston, MA; American Society of Clinical Oncology’s (ASCO) CancerLinQ, Alexandria, VA; ACORN Research LLC, Memphis, TN; Tempus, Chicago, IL
At: 2019 ASCO Annual Meeting, Poster Session

Read the full text here >>

Using Artificial Intelligence to Improve Capture of Metastatic Breast Cancer Status in Electronic Health Records

Author(s): Agrawal S*, Colano V, Chandrashekaraiah P, Vaidya VP, Charest F, Manirevu SVK, Inbar O, Jun MP, Stepanski EJ, Walker MS, Peevyhouse A, Narayanan B, Hyde B
At: 2019 ASCO Annual Meeting, Poster Session

Read the full text here >>

Assessing the real-world cost of care in patients with metastatic triple negative breast cancer (mTNBC) in the United States.

Skinner KE, Dufour R, Haiderali A, Huang M, Schwartzberg LS.
In: ISPOR Europe; 2018 November 10-14; Barcelona, Spain; 2018.

Read the full text here >>

Understanding health-related quality of life (HRQoL) in unresected stage III non-small cell lung cancer (NSCLC).

Ryan KJ, Skinner KE, Fernandes AW, Walker MS, Pavilack M, Punekar RS, VanderWalde NA.
In: ASCO Quality Care Symposium; 2018 September 28-29; Phoenix, AZ; 2018.

Read the full text here >>

Treatment outcomes in patients with metastatic neuroendocrine tumors: a retrospective analysis of a community oncology database.

Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS.
In: Journal of Gastrointestinal Cancer 2018 August 18; https://doi.org/10.1007/s12029-018-0160-x.

Read the full text here >>

Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015.

Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS.
In: Clinical Genitourinary Cancer 2018 August 10, https://doi.org/10.1016/j.clgc.2018.07.025.

Read the full text here >>

Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary.

Walker MS, Weinstein L, Luo R, Marino I.
In: Journal of Comparative Effectiveness Research 2018; 7(6):523-533.

Read the full text here >>

Patient reported outcomes in metastatic renal cell carcinoma patients receiving pazopanib in a community oncology setting.

Fisher MD, Ghate SR, Miller PJ, Walker MS, Ferrusi IL, Agarwal N.
In: ISPOR 23rd Annual International Meeting; 2018 May 19-23; Baltimore, MD; 2018.

Read the full text here >>

Impacts of time spent on rituximab infusion on patient satisfaction, stress, employment, and caregiver burden.

Fisher MD, Wallick CJ, Miller PJ, Walker MS, Lash S, Dawson KL, Reyes CM.
In: ISPOR 23rd Annual International Meeting; 2018 May 19-23; Baltimore, MD; 2018.

Read the full text here >>

Time spent on rituximab infusion and its impact on patient and caregiver burden

Fisher MD, Wallick CJ, Miller PJ, Walker MS, Lash S, Dawson KL, Reyes CM.
In: AMCP Managed Care and Specialty Pharmacy Annual Meeting; 2018 April 23-26; Boston, MA; 2018.

Read the full text here >>

Patient characteristics and costs in recurrent or refractory head and neck cancer: retrospective analysis of a community oncology database.

Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M.
In: Clinical Therapeutics 2018; 40(4):562-573.

Read the full text here >>

Effectiveness outcomes in patients with recurrent or refractory head and neck cancers: retrospective analysis of data from a community oncology database.

Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M.
In: Clinical Therapeutics 2018; 40(9):1522-1537.

Read the full text here >>

Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.

Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A.
In: Journal of Medical Economics 2018; 21(2): 192-200.

Read the full text here >>

Real-world clinical outcomes in BRCA-positive metastatic breast cancer patients treated in the community oncology setting.

Houts AC, Olufade T, Shenolikar R, Walker MS.
In: San Antonio Breast Cancer Symposium; 2017 December 5-9; San Antonio, TX; 2017.

Read the full text here >>

Treatment patterns and outcomes in patients with KRAS wild-type metastatic colorectal cancer treated in first line with bevacizumab- or cetuximab-containing regimens.

Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS.
In: Journal of Gastrointestinal Cancer 2017 Nov 22; https://doi.org/10.1007/s12029-017-0027-6.

Read the full text here >>

Progression-free survival in patients receiving chemotherapy alone (C) or chemotherapy with bevacizumab (CB) for first-line treatment of KRAS mutant metastatic colorectal cancer in community oncology settings.

Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS.
In: Journal of Gastrointestinal Cancer 2017 Oct 23; https://doi.org/10.1007/s12029-017-0017-8.

Read the full text here >>

Health care cost in patients with advanced non-small cell lung cancer and disease progression on targeted treatment in a real-world setting.

Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A.
In: Academy of Managed Care Pharmacy (AMCP) Nexus; 2017 October 16-19; Dallas, TX; 2017.

Read the full text here >>

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.

Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.
In: Medical Oncology 2017;34:193.

Read the full text here >>

Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer.

Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJE, Schwartzberg LS, Stepanski EJ, Marciniak M.
In: Psycho-Oncology 2017; 26(6): 755-762.

Read the full text here >>

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.

Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS.
In: Health and Quality of Life Outcomes 2017; 15:160.

Read the full text here >>

Treatment patterns and outcomes in metastatic bladder cancer in community oncology settings.

Fisher MD, Shenolikar R, Miller PJ, Walker MS, Fenton M.
In: American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU); 2017 February 16-18; Orlando, FL; 2017.

Read the full text here >>

Patient characteristics and costs in advanced head and neck cancer: retrospective analysis of a community oncology database.

Fisher MD, Fernandes AW, Miller PJ, Walker MS, Fenton M.
In: Academy of Managed Care Pharmacy (AMCP) Nexus; 2016 October 3-6; National Harbor, MD; 2016.

Read the full text here >>

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.

Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.
In: Medical Oncology 2017;34:193.

Read the full text here >>

Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer.

Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJE, Schwartzberg LS, Stepanski EJ, Marciniak M.
In: Psycho-Oncology 2017; 26(6): 755-762.

Read the full text here >>

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.

Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS.
In: Health and Quality of Life Outcomes 2017; 15:160.

Read the full text here >>

Maximizing the utility of real-world evidence: integration of structured electronic medical record (EMR) data, unstructured EMR data, and billing data for economics and outcomes research in oncology.

Walker MS, Ravelo A, Schulman K, Saverno K.
In: Value & Outcomes Spotlight 2017;3(5):11-13.

Read the full text here >>

Treatment patterns and outcomes in metastatic bladder cancer in community oncology settings.

Fisher MD, Shenolikar R, Miller PJ, Walker MS, Fenton M.
In: American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU); 2017 February 16-18; Orlando, FL; 2017.

Read the full text here >>

Patient characteristics and costs in advanced head and neck cancer: retrospective analysis of a community oncology database.

Fisher MD, Fernandes AW, Miller PJ, Walker MS, Fenton M.
In: Academy of Managed Care Pharmacy (AMCP) Nexus; 2016 October 3-6; National Harbor, MD; 2016.

Read the full text here >>

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer.

Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez-MacGregor M, Liede A, Arellano J, Balakumaran A, Qian Y.
In: Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Supportive Care in Cancer 2016;24(8):3557-3565.

Read the full text here >>

Effect of brain metastasis on patient reported outcomes in advanced NSCLC treated in real world community oncology settings.

Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS.
In: International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington, DC; 2016.

Read the full text here >>

Impact of disease progression on patient reported outcomes in advanced NSCLC: evidence from patients treated in real world community oncology settings

Walker MS, Wong W, Ravelo A, Hazard S, Miller PJE, Schwartzberg LS.
In: International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington, DC; 2016.

Read the full text here >>

Effectiveness outcomes in patients with advanced NSCLC treated in real world community oncology settings: results from a prospective medical record registry study.

Walker MS, Wong W, Ravelo A, Hazard S, Miller PJE, Schwartzberg LS.
In: International Society for Pharmacoeconomics and Outcomes Research; 2016 May 21-25; Washington, DC; 2016.

Read the full text here >>

Treatment outcomes in patients with metastatic neuroendocrine tumors: retrospective analysis of a community oncology database.

Fisher MD, Pulgar S, Kulke MH, Pitmann-Lowenthal S, Cox D, Miller PJ, et al.
In: National Comprehensive Cancer Network; 2016 March 31 - April 2; Hollywood, FL; 2016.

Read the full text here >>

Treatment patterns and outcomes in patients with KRAS wild type metastatic colorectal cancer (WTMCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.

Houts AC, Ogale S, Walker MS, Sommer N.
In: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI); 2016 January 21 - 23; San Francisco, CA; 2016.

Read the full text here >>

The impact of extended endocrine therapy on symptom burden and health-related quality of life in patients with early-stage breast cancer (ESBC).

Fisher MD, Schroeder BE, Miller PJE, Schnabel CA, Schwartzberg L, Walker MS.
In: San Antonio Breast Cancer Symposium; 2015 December 8 - 12; San Antonio, TX; 2015.

Read the full text here >>

Treatment patterns and outcomes in metastatic neuroendocrine tumors: results from a retrospective community oncology database.

Fisher MD, Pulgar S, Kulke MH, Pitmann-Lowenthal S, Cox D, Miller PJ, et al.
In: North American Neuroendocrine Tumor Society Symposium; 2015 October 15 - 17; Austin, TX; 2015.

Read the full text here >>

Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR.
In: Journal of Oncology Practice 2015;11(6): 491-497.

Read the full text here >>

Real-world impact of treatment-induced peripheral neuropathy of patient-reported outcomes in patients with multiple myeloma in the United States.

Walker MS, Cong Z, Knopf KB, Aggarwal S, Kerr J, Houts AC.
In: Multinational Association of Supportive Care in Cancer; 2015 June 25-27; Copenhagen, Denmark; 2015.

Read the full text here >>

Treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer at US community oncology practices.

Buck PO, Saverno KR, Miller PJE, Arondekar B, Walker MS.
In: Clinical Lung Cancer 2015;16(6):486 - 495.

Read the full text here >>

US burden of illness associated with adjuvant therapy for stage I-III melanoma.

Houts AC, Ward MA, Oglesby A, Walker MS, Saverno K.
In: International Society for Pharmacoeconomic and Outcomes Research; 2015 May 16 - 20; Philadelphia, PA; 2015.

Read the full text here >>

Maximizing the utility of real world evidence: integration of structured EMR data, unstructured EMR data, and billing data for economics and outcomes research in oncology.

Walker MS, Schulman K, Ravelo A, Saverno K.
In: International Society for Pharmacoeconomic and Outcomes Research; 2015 May 16 - 20; Philadelphia, PA; 2015.

Read the full text here >>

Treatment outcomes in patients with metastatic neuroendocrine tumors: a retrospective analysis of a community oncology database.

Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson S, Miller PJE, Somer B.
In: Journal of Community & Supportive Oncology 2014;12(9):321-328.

Read the full text here >>

Real-world outcomes in metastatic renal cell carcinoma: insights from a joint community-academic registry.

Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski EJ, Abernethy AP.
In: Journal of Oncology Practice 2014;10(2):e63-72.

Read the full text here >>

Use of “Real world” data to describe adverse events for the treatment of metastatic renal cell carcinoma in routine clinical practice.

Hirsch BR, Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP.
In: Medical Oncology 2014;31(9).

Read the full text here >>

Real-world treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer (NSCLC) at community oncology practices in the US.

Buck PO, Walker MS, Saverno KR, Miller PJE, Arondekar B.
In: Association of Managed Care Pharmacy Nexus Meeting; 2014 October 8 - 9; Boston, MA; 2014.

Read the full text here >>

Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient reported symptom burden.

Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS.
In: Breast Cancer Research and Treatment 2014;144(3):673-681.

Read the full text here >>

Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.

Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ.
In: International Journal of Dermatology 2014;53(11):e499 - e506.

Read the full text here >>

Clinical trial subjects compared to patients treated in "real world" practice: generalizability of renal cell carcinoma trials.

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR.
In: Annual Meeting of the American Society of Clinical Oncology; 2014 May 30 - June 3; Chicago, IL; 2014.

Read the full text here >>

Treatment patterns and baseline characteristics of a prospective cohort of patients with advanced NSCLC treated in real world community oncology settings.

Walker MS, Ravelo A, Miller PJE.
In: International Society for Pharmacoeconomic and Outcomes Research; 2014 May 31 – June 4; Montreal, Quebec, Canada; 2014.

Read the full text here >>

Association of treatment induced peripheral neuropathy with treatment patterns and outcomes in patients with newly diagnosed multiple myeloma.

Walker MS, Kerr J, Martin MG, Panjabi S, T.G. Martin III.
In: Annual Meeting of the Association of Managed Care Pharmacy; 2014 April 1 - 4; Tampa, Florida; 2014.

Read the full text here >>

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer.

Cleeland C, Moos Rv, Walker M, Wang Y, Gao J, Liede A, Arellano J, Balakumaran A, Qian Y.
In: San Antonio Breast Cancer Symposium; 2013 December 10-14; San Antonio, TX; 2013.

Read the full text here >>

“Real world” treatment of metastatic renal cell carcinoma in a joint community- academic cohort: progression-free survival over three lines of therapy.

Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Kirkendall DT, Stepanski EJ, Abernethy AP.
In: Clinical Genitourinary Cancer 2013;11(4):441-50.

Read the full text here >>

Association of treatment induced peripheral neuropathy (TIPN) with treatment patterns and outcomes in patients with newly diagnosed multiple myeloma.

Martin TG, Panjabi S, Kerr J, Martin MG, Walker MS.
In: Annual Meeting of the American Society of Hematology; 2013 December 7 - 10; New Orleans, LA; 2013.

Read the full text here >>

Community oncology treatment patterns and clinical effectiveness in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after docetaxel.

Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson S, Miller PJE, Somer B.
In: American Society of Clinical Oncology Quality Care Symposium; 2013 November 1 - 2; San Diego, CA; 2013.

Read the full text here >>

Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma in the community oncology setting.

Walker MS, Schwartzberg LS, Chen DM, Ramanan DD, Houts AC, Reyes C.
In: Journal of Cancer Therapy 2013;4:24-31.

Read the full text here >>

Early treatment discontinuation and switching in 1st line metastatic breast cancer: impact of symptom burden in a real world sample.

Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Schwartzberg LS.
In: ESMO European Cancer Congress 2013; 2013 September 27 - October 1; Amsterdam, Netherlands; 2013.

Read the full text here >>

Adverse events (AEs) by age: data from a real world, multicenter registry of patients treated for metastatic renal cell carcinoma (mRCC).

Harrison MR, Hirsch BR, Walker MS, Roe L, Chen C, Korytowsky B, Stepanski E, George DJ, Abernethy AP.
In: ESMO European Cancer Congress 2013; 2013 September 27 - October 1; Amsterdam, Netherlands; 2013.

Read the full text here >>

Real world symptom burden and early treatment discontinuation in 1st line metastatic breast cancer.

Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Ogbata O, Schwartzberg LS.
In: Annual Meeting of the American Society of Clinical Oncology; 2013 May 31 - June 4; Chicago, IL; 2013

Read the full text here >>

Anemia-related costs and adverse event rates in cancer patients who do not respond to erythropoietin stimulating agents.

Landsman-Blumberg P, Shi N, Varker H, Juneau P, Girvan A, Pohl G, Lau J, Bowman L.zberg LS.
In: Annual Meeting of the Association for Value-Based Cancer Care Conference; 2013 May 2 - 5; Hollywood, FL; 2013.

Read the full text here >>

Use of a validated assessment tool demonstrates the frequency of patient-experienced, regimen-related side effects associated with the treatment of common solid tumors.

Miles K, Weidner SM, Sonis ST, Walker M, Chandler J.
In: Oncology Nursing Society 38th Annual Congress; 2013 April 25-28; Washington, DC; 2013.

Read the full text here >>

The association of skin rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.

Stepanski EJ, Reyes C, Walker MS, Hoang SS, Leon L, Wojtowicz-Praga S, Miller PJE, Houts AC, Schwartzberg LS.
In: Pancreas 2013;42(1):32-6.

Read the full text here >>

Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.

Walker MS, Miller PJE, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS.
In: Journal of Medical Economics 2013;16(1):179-189.

Read the full text here >>

Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs).

Sonis ST, Schwartzberg LS, Walker MS, Weidner SM, Alterovitz G.
In: American Society of Clinical Oncology, Gastrointestinal Cancers Symposium; 2013 January 24 - 26; San Francisco, CA; 2013.

Read the full text here >>

KRAS testing of mCRC patients in a community-based oncology setting.

Carter GC, Landsman-Blumberg PB, Johnson BH, Sedgley R, Shankaran V.
In: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI); 2013 January 24 - 26; San Francisco, CA; 2013.

Read the full text here >>

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer.

Walker MS, Yu E, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS.
In: BMC Research Notes 2012;5:314.

Read the full text here >>

Using text mining of electronic medical records to identify KRAS testing status in mCRC patients.

Miller PJE, Walker MS, Landsman-Blumberg PB, Carter GC.
In: International Society for Pharmacoeconomic and Outcomes Research; 2013 May 18-22; New Orleans, LA; 2013

Read the full text here >>

Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma (aBCC) in the community oncology setting.

Walker MS, Schwartzberg LS, Chen DM, Ramanan D.
In: American Academy of Dermatology; 2012 March 6 - 20; San Diego, CA; 2012.

Read the full text here >>

Treatment patterns among patients with metastatic melanoma treated in the community oncology setting.

Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ.
In: The 8th International Congress of The Society for Melanoma Research; 2011 November 9 - 11; Tampa, FL; 2011.

Read the full text here >>

“Real world” treatment of metastatic renal cell carcinoma (mRCC) in community and academic settings.

George DJ, Walker MS, Hudson LL, Chen C, Korytowsky B, Harrison MR, Stepanski E, Abernethy AP.
In: Annual Meeting of the Kidney Cancer Association; 2011 October 14 - 15; Chicago, IL; 2011.

Read the full text here >>

Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation.

Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS.
In: Therapeutic Advances in Hematology 2011;2(3):129-139.

Read the full text here >>

Treatment patterns, medical resource use, and costs associated with second line treatment of non small cell lung cancer.

Walker MS, Pohl GM, Peltz G, Stepanski EJ, Faries D, Marciniak MD, Schwartzberg LS.
In: Chicago Multidisciplinary Symposium in Thoracic Oncology; 2010 December 9-11, 2010; Chicago, IL; 2010.

Read the full text here >>

Use of the Patient Care Monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV.

Houts AC, Lipinski D, Olsen JP, Baldwin S, Hasan M.
In: Psycho-Oncology 2010;19(4):399-407.

Read the full text here >>

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.

Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, et al.
In: Journal of Pain and Symptom Management 2010;40(4):545-58.

Read the full text here >>

The effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients.

Hasan M, Walker M, Yim YM, Yu E, Stepanski E, Schwartzberg L.
In: San Antonio Breast Cancer Symposium; 2009 December 9 - 13; San Antonio, TX; 2009.

Read the full text here >>

Symptom burden in patients with follicular lymphoma undergoing maintenance treatment with Rituxan compared with observation.

Walker M, Stepanski E, Reyes C, Hasan M, Schwartzberg L.
In: Annual Meeting of the American Society of Hematology; 2009 December 5 - 9; New Orleans, LA; 2009.

Read the full text here >>

Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.

Schwartzberg LS, Cobb P, Senecal F, Henry D, Kulig K, Walker MS, Houts AC, Stepanski EJ.
In: The Breast 2009;18(2):78-83.

Read the full text here >>

A retrospective study of quality of life in a community sample of patients with early stage breast cancer.

Walker MS, Schwartzberg LS, Stepanski EJ, Fortner BV.
In: Breast Cancer Research and Treatment 2009;115(2):415-422.

Read the full text here >>

The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer.

Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong J, Houts AC.
In: Journal of Clinical Sleep Medicine 2009;5(2):132-136.

Read the full text here >>

Psychosocial impact of cancer related symptoms among patients with lung cancer.

Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M.
In: Annual Meeting of the American Society of Clinical Oncology; 2009 May 29 - June 2; Orlando, FL; 2009.

Read the full text here >>

Psychosocial impact of cancer related symptoms among patients with lung cancer.

Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M.
In: Annual Meeting of the American Society of Clinical Oncology; 2009 May 29 - June 2; Orlando, FL; 2009.

Read the full text here >>

Psychosocial impact of cancer related symptoms among patients with lung cancer.

Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M.
In: Annual Meeting of the American Society of Clinical Oncology; 2009 May 29 - June 2; Orlando, FL; 2009.

Read the full text here >>

Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.

Abernethy AP, Herndon JE, 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK.
In: Journal of Pain and Symptom Management 2009;37(6):1027-38.

Read the full text here >>

Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: Assessment of clinical consequences.

Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC.
In: Supportive Care in Cancer 2008;16(4):393-398.

Read the full text here >>

Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.

Abernethy AP, Herndon JE, 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK.
In: Journal of Pain and Symptom Management 2009;37(6):1027-38.

Read the full text here >>

Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.

Abernethy AP, Herndon JE, 2nd, Wheeler JL, Patwardhan M, Shaw H, Lyerly HK, Weinfurt K.
In: Health Services Research 2008;43(6):1975-91.

Read the full text here >>

Relation of sleep disturbance, depression, pain, and fatigue in patients with cancer.

Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ.
In: Mechanisms and Treatment of Cancer-Related Symptoms Conference, MD Anderson Cancer Center; 2008 January 24 - 26; Houston, TX; 2008.

Read the full text here >>

Relation of sleep disturbance, depression, pain, and fatigue in patients with cancer.

Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ.
In: Mechanisms and Treatment of Cancer-Related Symptoms Conference, MD Anderson Cancer Center; 2008 January 24 - 26; Houston, TX; 2008.

Read the full text here >>

Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting.

Fortner BV, Schwartzberg LS, Stepanski EJ, Houts AC.
In: Supportive Cancer Therapy 2007;4(4):233-240.

Read the full text here >>

Practice patterns of community based adjuvant hormonal therapy (AHT) in early stage breast cancer (ESBC).

Schwartzberg LS, Cobb P, Kulig K, Walker MS, Stepanski EJ, Fortner BV.
In: ASCO Breast Cancer Symposium; 2007 September 7-8; San Francisco, CA; 2007.

Read the full text here >>

Willingness to pay to prevent chemotherapy induced nausea and vomiting.

Miller PJE, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS.
In: Annual Meeting of the American Society of Clinical Oncology; 2011 June 3 - 7; Chicago, IL; 2011.

Read the full text here >>

Prevalence of insomnia and associated symptoms in patients with cancer.

Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Fu D, Fortner BV.
In: Annual Meeting of the American Society of Clinical Oncology; 2007 June 1 - 5; Chicago, IL; 2007.

Read the full text here >>

Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation.

Fortner B, Baldwin S, Schwartzberg L, Houts AC.
In: Journal of Pain and Symptom Management 2006;31(3):207-14.

Read the full text here >>

Psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients.

Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC.
In: Journal of Pain and Symptom Management 2003;26(6):1077-92.

Read the full text here >>